Overview

A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

Status:
Completed
Trial end date:
2007-09-06
Target enrollment:
Participant gender:
Summary
To assess safety of SB-656933 following repeat dosing for 14 days.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Simvastatin